Highlights
- A randomized, placebo-controlled, Phase 3 trial demonstrated the safety and efficacy of MDMA-assisted therapy for the treatment of severe posttraumatic stress disorder (PTSD)
- Participants met DSM-5 criteria for severe PTSD and were permitted to have current mild or moderate (early remission) alcohol or cannabis use disorder
- Outcomes on standardized measures of hazardous alcohol (i.e., Alcohol Use Disorder Identification Test; AUDIT) and drug (i.e., Drug Use Disorder Identification Test; DUDIT) use at baseline prior to randomization and at study termination were examined
- Compared to Placebo+Therapy, MDMA-assisted therapy was associated with greater decreases on the AUDIT and no differential changes on the DUDIT
- MDMA-assisted therapy was not associated with increased risk for illicit substance use and may show beneficial effects on alcohol consumption and risk for hazardous use
Read the article from the journal Drug and Alcohol Dependence
